



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	09/993045
				Filing Date	November 13, 2001
				First Named Inventor	Timothy Brazelton
				Art Unit	1632
				Examiner Name	Q. J. Li
Sheet	1	of	1	Attorney Docket Number	SUPP-P01-016

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	AR	Chen, J., et al., "Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats" <i>Stroke</i> , 32(4): 1005-1011 (2001).				
	AS	Six, I., et al., "Beneficial Effect of Pharmacological Mobilization of Bone Marrow in Experimental Cerebral Ischemia" <i>Eur J Pharmacol</i> , 458(3): 327-328 (2003).				
	AT	Hess, D.D., et al., "Bone Marrow as a Source of Endothelial Cells and NeuN-Expressing Cells After Stroke" <i>Stroke</i> , 33(5): 1362-1368 (2002).				
	AU	Sanchez-Ramos, J., et al., "The X-gal Caution in Neural Transplantation Studies" <i>Cell Transplantation</i> , 9: 657-667 (2000).				
	AV	Neito-Sampedro, M., et al., "Injury-Induced Neurotrophic Activity in Adult Rat Brain: Correlation with Survival of Delayed Implants in the Wound Cavity" <i>J Neurosci.</i> , 3(11): 2219-2229 (1983).				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	8/25/04
-----------------------	--	--------------------	---------